Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
44.08 CHF | +2.55% | -.--% | -6.91% |
May. 28 | Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License | MT |
May. 27 | Bristol Myers: will present data on schizophrenia | CF |
Sales 2024 * | 46.09B 42.07B | Sales 2025 * | 46.06B 42.04B | Capitalization | 82.08B 74.93B |
---|---|---|---|---|---|
Net income 2024 * | -5.41B -4.94B | Net income 2025 * | 10.22B 9.33B | EV / Sales 2024 * | 2.63 x |
Net Debt 2024 * | 39.03B 35.63B | Net Debt 2025 * | 31.68B 28.92B | EV / Sales 2025 * | 2.47 x |
P/E ratio 2024 * |
-15.4
x | P/E ratio 2025 * |
7.66
x | Employees | - |
Yield 2024 * |
5.94% | Yield 2025 * |
6.24% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
1 day | +2.55% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+12.94% | 238B | |
+7.01% | 204B | |
-6.50% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- BMY Stock
- BMY Stock